Harry Domash is a long-standing expert on income investing; in his latest Dividend Detective, he hig...
3 "Autopilot" Funds with 8% Yields
07/01/2019 5:00 am EST
Our subscriber mailbag served up an important question from a reader this week. What are the perfect retirement dividends to buy and hold forever? notes Brett Owens, fund specialist and editor of Contrarian Outlook.
This investor is retired and manages investments for him and his wife. He asked me how to build a portfolio that will give her reliable income, with little maintenance, if he can no longer look after their investments himself. It’s a great question, and one that’s likely occurred to you, too. So let’s tackle it.
While we always feel you should at least check in on your investments from time to time, let’s go ahead and piece together a portfolio we’d feel pretty comfortable buying and tucking away for the long term. We’re going to do it with just three buys.
When we’re done, our three-fund portfolio will hand us a diverse collection of investments built to hold up in any market, throw off a steady 8% dividend and pay monthly dividends, to boot. A monthly payout that large gives us four critical advantages:
- The ability to live on dividends alone: with a $500K nest egg, our portfolio would pay $40,000 in yearly dividends, more than enough for a healthy retirement for most folks—especially for a single person.
- No daily ticker parade, because as long as your dividends are secure (and covering your bills), why would you want to stay glued to the market’s daily gyrations?
- Faster reinvestment: With monthly dividends and a dividend reinvestment plan, our portfolio will automatically reinvest our payouts faster than with quarterly dividends, enhancing our return further.
- A legacy: With your principal intact, you can leave more cash to your kids (or grandkids) to pay for education, for example, or maybe help buy a first home.
We’re going to add one “safety valve” to keep our “autopilot” portfolio off the rocks: professional management. Because if we’re not around to manage our investments, we risk our portfolio running into a “dividend dumpster fire” like General Electric (GE) and not being able to bail out!
So how are we going to hire our “managers”? Simple. By investing in actively managed closed-end funds (CEFs) These funds are famous for their high yields, with payouts of 7% and up common in the CEF space.
I’m going to show you three of the most established CEFs in the business. All are run by smart money minds, and all trade at serious discounts that lock in our upside (and hedge our downside, too). Here they are:
Now let’s take a look at each of our picks individually:
Eaton Vance Tax-Advantaged Global Dividend Income Fund (ETG)
Despite the “global” in its name, the Eaton Vance Tax-Advantaged Global holds a large portion of its portfolio in the US (41.5%), with most of the rest in Europe (53.2%) and the Asia-Pacific (4.4%).
ETG also holds “megatrend” stocks like France’s Veolia Environnement SA (VEOEY), which helps companies cut pollution and boost efficiency—a business that will never go cold, particularly in these climate-obsessed times.
Another thing that makes ETG perfect for our “autopilot” portfolio: one of the steadiest CEF dividends out there. This fund yields 7.9%, and its dividend has held steady for more than a decade.
Finally, ETG trades at an 8.5% discount to net asset value (NAV, or the value of its portfolio), well below its five-year average of 7.1%. So we’ve got plenty of upside ahead as its discount reverts back to its normal level.
Tekla Healthcare Opportunities Fund (THQ)
Tekla Healthcare Opportunities is our youngest fund — barely five years old — but its bench strength is as strong as you can get. It is run by Tekla Capital Management, a Boston firm with a team of medical doctors and boots-on-the-ground researchers.
Dr. Daniel R. Olmstead runs Tekla, which he joined nearly 20 years ago. His researchers come from big players, like Merck & Co. (MRK), as well as tiny biotech firms.
If you’ve been investing in pharma stocks for a while, you know that success here is all about a company’s drug pipeline. And THQ’s savvy crew gives us the closest thing to inside knowledge of these firms’ pipelines we can get.
Their approach has paid off: THQ has pummeled the iShares US Pharmaceuticals ETF (IHE), including dividends, since the CEF's launch in January 2014. And thanks to Tekla Healthcare Opportunities' mammoth 7.9% dividend (compared to just 1.2% for IHE), most of that return was in cash.
These days, our pharma all-stars are honing in on some of the biggest companies in the space, with the most robust pipelines, including Pfizer (PFE), Amgen (AMGN) and Gilead Sciences (GILD). THQ also holds a few non-pharma names, like health insurer Anthem (ANTM).
Overwrought fears of lower healthcare spending, driven by Democrats’ “Medicare for all” proposals, have weighed on pharma stocks. That’s made THQ a bargain, at a 10.4% discount to NAV, well below its five-year average of 7.7%.
That’s way too cheap for a fund paying 7.9% today and whose monthly dividend has held steady (not to mention a one-time special dividend paid a few years ago) since inception. The time to move on THQ is now—then you can lock it up for decades.
Western Asset High Income Fund II (HIX)
Western Asset High Income II is a high-yield bond fund with a long history of strong performance. The fund, run by Legg Mason (LM), which has been in the fixed-income business for 48 years, has tripled in value (including dividends) since its IPO in the late 1990s, crushing the S&P 500.
HIX gives investors that strong return while yielding 8.3%. Legg Mason generates HIX’s payout through a portfolio that includes high-yield corporate bonds (61.4%), emerging-market debt (22.2%), bank loans (6.5%) and investment-grade corporate bonds (5.9%).
And if you’re worried about rising interest rates hurting HIX, don’t be: the average duration of its bond holdings is a long 6.2 years, and long-duration bonds tend to perform well as rates fall.
We’ve already seen that in action since January, when Fed Chair Jerome Powell put interest rates on pause — and HIX’s gains have accelerated now that rate cuts — possibly starting as early as July — are on the table.
The fund’s historically high total return and consistent share-price performance make it a good fit for our “autopilot” portfolio. The fact that it’s trading at an 8.5% discount to NAV— well below its five-year average of 4.9% — makes it particularly compelling now.
Related Articles on DIVIDEND
Here is a potential income generating trade in the SPY, from Jay Soloff....
The Timely Ten represents our top ten recommendations from the Undervalued category each month, asse...
An investor recently asked us if we could help him get a solid dividend portfolio set up to kick off...